FDA Accepts Supplemental NDA for Mekinist by Novartis
The FDA has accepted a supplemental NDA for Mekinist (trametinib dimethyl sulfoxide) submitted by Novartis.
Asset / Drug
Drug and asset intelligence for Mekinist with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
MEK Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.